 |
|
| Overview |
 |
| Antibody-peptide conjugation is a bioconjugation technique that combines the unique properties of antibodies (high specificity, long half-life) with peptides (small size, multifunctionality) to create hybrid molecules for targeted therapeutic, diagnostic, and research applications. Antibody-peptide conjugates bridge the gap between biologics and small molecules, offering a versatile platform for precision medicine. Their modularity, safety, and efficacy make them ideal for next-generation therapies. |
|
| Structure and Therapeutic Applications of APCs |
|
| Antibody-peptide conjugates (APCs) are hybrid molecules composed of three core elements: |
|
 |
| • |
Antibody Scaffold: Typically a monoclonal antibody (e.g., IgG) with antigen-binding variable regions (Fab) for target recognition and constant regions (Fc) for immune effector functions. |
| • |
Functional Peptide: A short peptide (5–30 amino acids) engineered for specific roles, such as cell penetration (e.g., TAT), immune modulation (e.g., cytokine mimetics), or payload delivery (e.g., toxins). |
| • |
Linker: A chemical or enzymatic bond (e.g., cleavable linker, non-cleavable linker) that covalently attaches the peptide to the antibody. Linkers may include cleavable elements (e.g., protease-sensitive sequences) for controlled payload release. |
|
|
| Advanced Antibody-Peptide Conjugation Solutions |
|
| Enhance the homogeneity, potency, and safety of your APCs thanks to IntegrateRNA’s flexible and diversified antibody-peptide conjugate service platform. Drawing from years of experience in APC development, our platform allies the high productivity of the CHO cell line with the high efficiency of click chemistry for antibody conjugation and robust bioanalytical methods. Obtain high-quality APC products with up to 90% of antibodies conjugated with the desired peptide-to-antibody (DAR) ratio. |
|
| Why choose IntegrateRNA |
| Proprietary Conjugation Platform |
 |
| Leverage our patented Site-Specific Technology, enabling precise, homogeneous conjugates with controlled drug-to-antibody ratios (DAR 2-8) and minimal aggregation. |
|
|
| End-to-End Expertise |
 |
| Full-service solutions from antibody engineering (humanization, affinity maturation) to peptide design (stabilization, functionalization) and in vivo validation. |
|
| Extensive Bioanalytical Capabilities |
 |
| Characterize DAR values, drug load distribution, % of free drug and antibody with high accuracy and precision to ensure high success rates during clinical development. |
|
|
| IP Free |
 |
| Keep full ownership of the antibodies developed for your APC applications |
|
|
| Antibody Peptide Conjugate Development Process |
 |
| 1. |
Target Validation & Antibody Engineering |
| 2. |
Peptide Design & Functionalization |
| 3. |
Conjugation Strategy Development |
| 4. |
Analytical & Quality Control (QC) |
|
|
| Specialized QC of APCs |
| Quality Control |
Project Type |
Analysis Items/Quality Inspection Items |
Method |
| Characteristic Analysis |
Primary Structure & Peptide Conjugation Sites |
Evaluate the impact of the conjugation process on the primary structure (such as amino acid sequence
integrity, disulfide bond linkage, glycosylation modification, and post – post-translational modification,
etc.) and the identification and analysis of conjugation sites |
N/A |
| Characteristic Analysis |
DAR Value & Drug Loading Distribution |
The average number and quantity distribution of cytotoxic drugs conjugated to each antibody molecule |
UV, HIC – HPLC, RP – HPLC, CE, LC – MS |
| Characteristic Analysis |
Molecular Size Variants |
Evaluate the degree of fragmentation and the degree of ADC aggregation caused by hydrophobic cytotoxic
drugs |
SEC – HPLC, SDS – PAGE, CE – SDS, AUC |
| Characteristic Analysis |
Charge Variants |
Evaluate the charge heterogeneity of antibodies after conjugation |
CZE, IEX – HPLC, CIEF, iCIEF |
| Characteristic Analysis |
Higher – order Structure |
Evaluate the structural heterogeneity of antibodies after conjugation |
CD, DSC, DLS, FT – IR |
| Characteristic Analysis |
Immunological Properties |
Evaluate the specificity of binding to the target antigen after conjugation and the consistency of binding
activity among batches |
ELISA, SPR |
| Characteristic Analysis |
Biological Activity |
Evaluate target – dependent cytotoxicity and Fc – mediated immunological activity (if any) |
ELISA or surface plasmon resonance method |
| Characteristic Analysis |
Process – related Impurities and Contaminants |
Free cytotoxic drugs and their related substances, residual solvents, heavy metals and other impurities |
N/A |
| Product Inspection |
Identification, DAR and drug loading distribution, purity and product – related impurities,
process – related impurities, potency, content, safety tests, and other items (appearance, visible foreign
matter, pH value, osmotic pressure, etc.) |
N/A |
| Stability Evaluation |
Long – term stability, accelerated stability, forced condition tests |
N/A |
|
|
 Schedule an Approintment |
| Connect with Creative Biogene at these upcoming events! |
| • |
Creative Biogene to Present at AACR Annual Meeting 2025
April 25-30, 2025 |
Chicago, Illinois |
Booth number #3339 |
Request a Meeting |
| • |
Meet Creative Biogene at ASGCT 28th Annual Meeting
May 13-17, 2025 |
New Orleans, Louisiana |
Booth number #1349 |
Request a Meeting |
|
 |
 |
Antibody-Peptide Conjugation |
|
|
|
Tel: 1-631-626-9181 (USA) 44-208-123-7131 (Europe) | Fax:
1-631-614-7828Email: info@biocart.org | SUITE
115, 17 Ramsey Road, Shirley, NY 11967, USA |
|
|
|
